Long-chain acylcarnitine deficiency promotes hepatocarcinogenesis

Despite therapy with potent antiviral agents, chronic hepatitis B (CHB) patients remain at high risk of hepatocellular carcinoma (HCC). While metabolites have been rediscovered as active drivers of biological processes including carcinogenesis, the specific metabolites modulating HCC risk in CHB pat...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kaifeng Wang, Zhixian Lan, Heqi Zhou, Rong Fan, Huiyi Chen, Hongyan Liang, Qiuhong You, Xieer Liang, Ge Zeng, Rui Deng, Yu Lan, Sheng Shen, Peng Chen, Jinlin Hou, Pengcheng Bu, Jian Sun
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-03-01
Col·lecció:	Acta Pharmaceutica Sinica B
Matèries:	Hepatocellular carcinoma Metabolomics H3K14 CUT&Tag Chemoprevention Long-chain acylcarnitine
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2211383525000231
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!